» Authors » Palmiero Monteleone

Palmiero Monteleone

Explore the profile of Palmiero Monteleone including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 184
Citations 4765
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzarotto F, Monteleone P, Minelli A, Mattevi S, Cascino G, Rocca P, et al.
Psychiatry Res . 2024 Aug; 340:116107. PMID: 39096746
Schizophrenia is a severe psychiatric disorder, associated with a reduction in life expectancy of 15-20 years. Available treatments are at least partially effective in most affected individuals, and personal resources...
2.
Cascino G, Di Lodovico L, Ceres R, Monteleone A, Gorwood P, Monteleone P
Int J Methods Psychiatr Res . 2024 Jun; 33(2):e2022. PMID: 38898737
Objective: The Videos of Physical Exercise and Sedentary Behaviours (VPESB) database is a novel database designed to experimentally investigate neural reactivity to physical exercise. The aim of this database is...
3.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Int J Bipolar Disord . 2024 Jun; 12(1):20. PMID: 38865039
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
4.
Tonna M, Borrelli D, Aguglia E, Bucci P, Carpiniello B, DellOsso L, et al.
Eur Psychiatry . 2024 Apr; 67(1):e37. PMID: 38682575
Background: Although obsessive-compulsive disorder (OCD) is highly prevalent in schizophrenia, its relationship with patients' real-life functioning is still controversial. Methods: The present study aims at investigating the prevalence of OCD...
5.
Ou A, Rosenthal S, Adli M, Akiyama K, Akula N, Alda M, et al.
Transl Psychiatry . 2024 Feb; 14(1):109. PMID: 38395906
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
6.
Monteleone P, Plessow F, Misra M
Psychoneuroendocrinology . 2024 Feb; 162:106978. PMID: 38350243
No abstract available.
7.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Res Sq . 2023 Dec; PMID: 38077040
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
8.
Galderisi S, Perrottelli A, Giuliani L, Pisaturo M, Monteleone P, Pagliano P, et al.
Eur Neuropsychopharmacol . 2023 Dec; 79:22-31. PMID: 38065006
Cognitive impairment (CI) is regarded as a remarkable burden in COVID-19 survivors. Its prevalence and profile, and relationships with the disease clinical and laboratory indices, remain unclear. The present study...
9.
Kelsoe J, Ou A, Rosenthal S, Adli M, Akiyama K, Akula N, et al.
Res Sq . 2023 Oct; PMID: 37886563
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
10.
Vita A, Barlati S, Deste G, Rossi A, Rocca P, Bertolino A, et al.
Eur Psychiatry . 2023 Oct; 66(1):e85. PMID: 37869966
Background: Autistic symptoms represent a frequent feature in schizophrenia spectrum disorders (SSD). However, the prevalence and the cognitive and functional correlates of autistic symptoms in unaffected first-degree relatives of people...